Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics

F. Eduati, R. Utharala, D. Madhavan, U.P. Neumann, T. Cramer, J. Saez-Rodriguez, C.A. Merten

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademic

Uittreksel

Functional screening of live patient cancer cells holds great potential for personalized medicine and allows to overcome the limited translatability of results from existing in-vitro and ex-vivo screening models. Here we present a plug-based microfluidics approach enabling the testing of drug combinations directly on cancer cells from patient biopsies. The entire procedure takes less than 48 hours after surgery and does not require ex vivo cultivation. We screened more than 1100 samples for different primary human tumors (each with 56 conditions and at least 20 replicates), and obtained highly specific sensitivity profiles. This approach allowed us to derive optimal treatment options which we further validated in two different pancreatic cancer cell lines. This workflow should pave the way for rapid determination of optimal personalized cancer therapies at assay costs of less than US$ 150 per patient.
TaalEngels
Aantal pagina's34
TijdschriftbioRxiv
DOI's
StatusGepubliceerd - 14 dec 2016
Extern gepubliceerdJa

Vingerafdruk

Microfluidics
Drug Combinations
Neoplasms
Precision Medicine
Workflow
Therapeutics
Pancreatic Neoplasms
Biopsy
Costs and Cost Analysis
Cell Line

Citeer dit

Eduati, F., Utharala, R., Madhavan, D., Neumann, U. P., Cramer, T., Saez-Rodriguez, J., & Merten, C. A. (2016). Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics. bioRxiv. DOI: 10.1101/093906
Eduati, F. ; Utharala, R. ; Madhavan, D. ; Neumann, U.P. ; Cramer, T. ; Saez-Rodriguez, J. ; Merten, C.A./ Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics. In: bioRxiv. 2016
@article{c03a276692e548f0a36cec67901f9e91,
title = "Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics",
abstract = "Functional screening of live patient cancer cells holds great potential for personalized medicine and allows to overcome the limited translatability of results from existing in-vitro and ex-vivo screening models. Here we present a plug-based microfluidics approach enabling the testing of drug combinations directly on cancer cells from patient biopsies. The entire procedure takes less than 48 hours after surgery and does not require ex vivo cultivation. We screened more than 1100 samples for different primary human tumors (each with 56 conditions and at least 20 replicates), and obtained highly specific sensitivity profiles. This approach allowed us to derive optimal treatment options which we further validated in two different pancreatic cancer cell lines. This workflow should pave the way for rapid determination of optimal personalized cancer therapies at assay costs of less than US$ 150 per patient.",
author = "F. Eduati and R. Utharala and D. Madhavan and U.P. Neumann and T. Cramer and J. Saez-Rodriguez and C.A. Merten",
year = "2016",
month = "12",
day = "14",
doi = "10.1101/093906",
language = "English",
journal = "bioRxiv",
publisher = "Cold Spring Harbor Laboratory Press",

}

Eduati, F, Utharala, R, Madhavan, D, Neumann, UP, Cramer, T, Saez-Rodriguez, J & Merten, CA 2016, 'Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics' bioRxiv. DOI: 10.1101/093906

Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics. / Eduati, F.; Utharala, R.; Madhavan, D.; Neumann, U.P.; Cramer, T.; Saez-Rodriguez, J.; Merten, C.A.

In: bioRxiv, 14.12.2016.

Onderzoeksoutput: Bijdrage aan tijdschriftTijdschriftartikelAcademic

TY - JOUR

T1 - Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics

AU - Eduati,F.

AU - Utharala,R.

AU - Madhavan,D.

AU - Neumann,U.P.

AU - Cramer,T.

AU - Saez-Rodriguez,J.

AU - Merten,C.A.

PY - 2016/12/14

Y1 - 2016/12/14

N2 - Functional screening of live patient cancer cells holds great potential for personalized medicine and allows to overcome the limited translatability of results from existing in-vitro and ex-vivo screening models. Here we present a plug-based microfluidics approach enabling the testing of drug combinations directly on cancer cells from patient biopsies. The entire procedure takes less than 48 hours after surgery and does not require ex vivo cultivation. We screened more than 1100 samples for different primary human tumors (each with 56 conditions and at least 20 replicates), and obtained highly specific sensitivity profiles. This approach allowed us to derive optimal treatment options which we further validated in two different pancreatic cancer cell lines. This workflow should pave the way for rapid determination of optimal personalized cancer therapies at assay costs of less than US$ 150 per patient.

AB - Functional screening of live patient cancer cells holds great potential for personalized medicine and allows to overcome the limited translatability of results from existing in-vitro and ex-vivo screening models. Here we present a plug-based microfluidics approach enabling the testing of drug combinations directly on cancer cells from patient biopsies. The entire procedure takes less than 48 hours after surgery and does not require ex vivo cultivation. We screened more than 1100 samples for different primary human tumors (each with 56 conditions and at least 20 replicates), and obtained highly specific sensitivity profiles. This approach allowed us to derive optimal treatment options which we further validated in two different pancreatic cancer cell lines. This workflow should pave the way for rapid determination of optimal personalized cancer therapies at assay costs of less than US$ 150 per patient.

U2 - 10.1101/093906

DO - 10.1101/093906

M3 - Article

JO - bioRxiv

T2 - bioRxiv

JF - bioRxiv

ER -

Eduati F, Utharala R, Madhavan D, Neumann UP, Cramer T, Saez-Rodriguez J et al. Rapid identification of optimal drug combinations for personalized cancer therapy using microfluidics. bioRxiv. 2016 dec 14. Beschikbaar vanaf, DOI: 10.1101/093906